Miscellaneous

| Source: Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk today announced plans to expand its diabetes care field force in the US, from around 1,200 to approximately 1,900 people. The expansion, which will take place during the first half of 2007, is designed to further strengthen Novo Nordisk's position in the US insulin market and to increase the company's 'share of voice' in the competitive market for diabetes products.
 
The US insulin market is a key growth market for Novo Nordisk and with its more than 40% share of this market (measured in volume) Novo Nordisk is today the clear market leader.
 
The field force expansion will support Novo Nordisk's complete portfolio of modern insulins (insulin analogues): Levemir®, a long-acting insulin, NovoLog® Mix 70/30 (NovoMix® 30 outside the US), a premixed formulation of rapid-acting and intermediate-acting insulin, and NovoLog® (NovoRapid® outside the US), a rapid-acting insulin. The expanded field force will make it possible to reach more primary care physicians and increase the frequency of visits to both primary care physicians and endocrinologists.
 
Martin Soeters, president of Novo Nordisk Inc, said: "So many people with diabetes are still not in acceptable glycaemic control. That is why we are very pleased to announce the significant field force expansion in the US market which will support our complete portfolio of insulin analogues as well as our leading insulin injection device, FlexPen®. The expansion will prepare our organisation for future launches of additional innovative diabetes products that we currently have in clinical development."
 
The expansion does not change the financial outlook for 2006 or the preliminary guidance for 2007 which was provided in Novo Nordisk's financial statement for the first nine months of 2006 on 27 October, based on the currency exchange rates prevailing at the end of October 2006

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,000 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
 
Contacts for further information:
E-mail: stj@novonordisk.com      E-mail: mlau@novonordisk.com
 
Stock Exchange Announcement no 36 / 2006